CoChat

Two Birds, One Stone: Double Hits on Tumor Growth and Lymphangiogenesis by Targeting Vascular Endothelial Growth Factor Receptor 3

Open access

The DOI matches its Crossref record; 160 of the 170 references it cites were found in a registry or an index.

Abstract

Vascular endothelial growth factor receptor 3 (VEGFR3) has been known for its involvement in tumor-associated lymphangiogenesis and lymphatic metastasis. The VEGFR3 signaling is stimulated by its main cognate ligand, vascular endothelial growth factor C (VEGF-C), which in turn promotes tumor progression. Activation of VEGF-C/VEGFR3 signaling in lymphatic endothelial cells (LECs) was shown to enhance the proliferation of LECs and the formation of lymphatic vessels, leading to increased lymphatic metastasis of tumor cells. In the past decade, the expression and pathological roles of VEGFR3 in tumor cells have been described. Moreover, the VEGF-C/VEGFR3 axis has been implicated in regulating immune tolerance and suppression. Therefore, the inhibition of the VEGF-C/VEGFR3 axis has emerged as an important therapeutic strategy for the treatment of cancer. In this review, we discuss the current findings related to VEGF-C/VEGFR3 signaling in cancer progression and recent advances in the development of therapeutic drugs targeting VEGF-C/VEGFR3.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells8030270

Cites

160 of 160 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The signaling pathways of vascular endothelial growth factors and vascular endothelial growth factor receptors (VEGFs/VEGFRs) and their biological functions. The three tyrosine kinase (TK) receptors have specific binding capabilities. VEGF-A, VEGF-B, and PLGF can bind to VEGFR1 and mediate its biological functions. The binding of VEGF-A, VEGFR-C, and VEGF-D can stimulate the activation of VEGFR2, resulting in cell proliferation and angiogenesis. VEGF-C and VEGF-D bind to VEGFR3 and induce downstream signaling which mediates cell survival and lymphangiogenesis. Neuropilin 1 (NRP1) and neuropilin 2 (NRP2) can function as co-receptors for VEGFR2 and VEGFR3. The binding of VEGF-A isoforms and NRP1 can form a complex with VEGFR2, leading to the induction of downstream signaling which regulates the proliferation and migration of endothelial cells. VEGF-C/D bind to NRP2 and forms a complex with VEGFR3, activating the VEGFR3 signaling which enhances the proliferation of lymphatic endothelial cells (LECs) and lymphangiogenesis. MKK4, Mitogen-activated protein kinase kinase-4; JNK1/2, c-Jun N-terminal kinase-1/2; PI3K, phosphoinositide-3 kinase; AKT/PKB, AKT/protein kinase B; PKC, protein kinase C; ERK, extracellular signal–related kinase; SHC-GRB2, Src homology domain containing growth factor receptor–bound protein 2.
Figure 1 The signaling pathways of vascular endothelial growth factors and vascular endothelial growth factor receptors (VEGFs/VEGFRs) and their biological functions. The three tyrosine kinase (TK) receptors have specific binding capabilities. VEGF-A, VEGF-B, and PLGF can bind to VEGFR1 and mediate its biological functions. The binding of VEGF-A, VEGFR-C, and VEGF-D can stimulate the activation of VEGFR2, resulting in cell proliferation and angiogenesis. VEGF-C and VEGF-D bind to VEGFR3 and induce downstream signaling which mediates cell survival and lymphangiogenesis. Neuropilin 1 (NRP1) and neuropilin 2 (NRP2) can function as co-receptors for VEGFR2 and VEGFR3. The binding of VEGF-A isoforms and NRP1 can form a complex with VEGFR2, leading to the induction of downstream signaling which regulates the proliferation and migration of endothelial cells. VEGF-C/D bind to NRP2 and forms a complex with VEGFR3, activating the VEGFR3 signaling which enhances the proliferation of lymphatic endothelial cells (LECs) and lymphangiogenesis. MKK4, Mitogen-activated protein kinase kinase-4; JNK1/2, c-Jun N-terminal kinase-1/2; PI3K, phosphoinositide-3 kinase; AKT/PKB, AKT/protein kinase B; PKC, protein kinase C; ERK, extracellular signal–related kinase; SHC-GRB2, Src homology domain containing growth factor receptor–bound protein 2.CC BY · PubMed Central
Figure 2 The function roles of VEGF-C/VEGFR3 signaling in tumor progression. The VEGF-C/VEGFR3 axis promotes tumor growth in autocrine and paracrine manners. VEGF-C can enhance the proliferation of LECs through VEGFR3, resulting in lymphangiogenesis and lymphatic metastasis of tumor cells. VEGF-C/VEGFR3 signaling can also mediate the functions of immune cells, including dendritic cells (DCs), macrophages, and natural killer (NK) cells.
Figure 2 The function roles of VEGF-C/VEGFR3 signaling in tumor progression. The VEGF-C/VEGFR3 axis promotes tumor growth in autocrine and paracrine manners. VEGF-C can enhance the proliferation of LECs through VEGFR3, resulting in lymphangiogenesis and lymphatic metastasis of tumor cells. VEGF-C/VEGFR3 signaling can also mediate the functions of immune cells, including dendritic cells (DCs), macrophages, and natural killer (NK) cells.CC BY · PubMed Central
Figure 3 Targeting the VEGF-C/VEGFR3 axis by various therapeutic strategies. The binding of VEGF-C/D to VEGFR3 induces downstream signaling which mediates cell survival and lymphangiogenesis. The treatment of small molecule receptor tyrosine kinase inhibitors (TKIs) inhibits the activation of VEGF-C/D/VEGFR3 signaling. Monoclonal antibody (mAb) and receptor trap target VEGF-C, preventing its binding to VEGFR3. Monoclonal antibody or peptides targeting VEGFR3 prevent the binding of VEGF-C, resulting in the inhibition of VEGFR3 signaling.
Figure 3 Targeting the VEGF-C/VEGFR3 axis by various therapeutic strategies. The binding of VEGF-C/D to VEGFR3 induces downstream signaling which mediates cell survival and lymphangiogenesis. The treatment of small molecule receptor tyrosine kinase inhibitors (TKIs) inhibits the activation of VEGF-C/D/VEGFR3 signaling. Monoclonal antibody (mAb) and receptor trap target VEGF-C, preventing its binding to VEGFR3. Monoclonal antibody or peptides targeting VEGFR3 prevent the binding of VEGF-C, resulting in the inhibition of VEGFR3 signaling.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 160 references

Research works printed but not linked: 1

  1. Shushanov, 2000, Vegfc and vegfr3 expression in human thyroid pathologies, Int. J. Cancer, 86, 47, 10.1002/(sici)1097-0215(20000401)86:1<47::aid-ijc7>3.0.co;2-r · doi:10.1002/(sici)1097-0215(20000401)86:1<47::aid-ijc7>3.0.co;2-r

Cited by

See all 67

Metadata

Authors
Hsu, M.-C., Pan, M.-R., & Hung, W.-C.
Affiliations
  • National Health Research Institutes (TW)
  • Kaohsiung Medical University (TW)
Corresponding author
Hung, Wen-Chun
Venue
Cells
Publisher
MDPI AG
Published
2019-03-21
Volume
8
Issue
3
Pages
270
ISSN
2073-4409 (ISSN-L)
OpenAlex
W2925306628
Cited by
67
References
170
Citations by year
2026: 5 · 2025: 11 · 2024: 10 · 2023: 7 · 2022: 10 · 2021: 11 · 2020: 7 · 2019: 6
FWCI
0.81
Type
journal article
Language
en
Open access
Locations
  • Cells (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Ministry of Science and Technology, Taiwan (MOST 103-2320-B-400-014; 104-2320-B-400 -010-MY3 and 107-2320-B-400-012)
Topics
  • Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Surgery › Lymphatic Disorders and Treatments
Keywords
VEGFR-3, VEGF-C, tumor growth, lymphangiogenesis, lymph node metastasis, lymphatic endothelial cells, tumor immune tolerance, anti-VEGF therapy, tumor progression
MeSH terms
Animals, Humans, Neoplasms, Signal Transduction, Vascular Endothelial Growth Factor Receptor-3, Lymphangiogenesis, Endothelial Cells, Cell Proliferation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Two Birds, One Stone: Double Hits on Tumor Growth and Lymphangiogenesis by Targeting Vascular Endothelial Growth Factor Receptor 3. https://app.cochat.ai/papers/10.3390/cells8030270
The paper
Hsu, M.-C., Pan, M.-R., & Hung, W.-C. (2019). Two Birds, One Stone: Double Hits on Tumor Growth and Lymphangiogenesis by Targeting Vascular Endothelial Growth Factor Receptor 3. Cells. https://doi.org/10.3390/cells8030270

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.